Pyrotinib Combined With Capecitabine in HER-2 Positive Advanced Breast Cancer and Brain Metastases (Post-PERMEATE)
Clinical trial NCT05359120 · UNKNOWN
Trial details
- NCT number
- NCT05359120
- Sponsor
- Henan Cancer Hospital
- Status
- UNKNOWN
- Study type
- OBSERVATIONAL
- Start date
- 2022-05-30
- Primary completion
- 2024-05-01
- Enrollment
- 300
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.